Non-ST-elevation myocardial infarction: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
==Treatment== | ==Treatment== | ||
*Dual antiplatelet therapy is key | |||
**ASA + other agent (other agent depends on conservative vs interventional strategy) | |||
***Medical management vs cath determined by level of risk for future cardiovascular events | |||
===Anti-ischemia=== | ===Anti-ischemia=== | ||
#Oxygen | #Oxygen | ||
| Line 35: | Line 39: | ||
===Antiplatelet=== | ===Antiplatelet=== | ||
#ASA | #ASA | ||
## | ##Recommended dose is 325mg chewed | ||
##Reduces death from MI by 12.5-6.4% | ##Reduces death from MI by 12.5-6.4% | ||
##Should be used in all ACS unless contraindicated | ##Should be used in all ACS unless contraindicated | ||
| Line 41: | Line 45: | ||
##Give in addition to ASA | ##Give in addition to ASA | ||
###300mg | ###300mg | ||
###600mg if going to PCI ( | ###600mg if going to PCI (superior in preventing post-proc MI) | ||
##Mortality benefit with NSTEMI | ##Mortality benefit with NSTEMI | ||
##Main risk and contraindication is bleeding | ##Main risk and contraindication is bleeding | ||
| Line 51: | Line 55: | ||
===Antithombotics=== | ===Antithombotics=== | ||
# | #Give heparin or enoxaparin along w/ ASA (Class 1A evidence) | ||
# | #Enoxaparin | ||
##1mg/kg | ##AHA recommends for moderate & high risk UA/NSTEMI unless CABG w/in 24hr | ||
##1mg/kg subq BID | |||
##Safer than UFH | ##Safer than UFH | ||
###ESSENCE showed 20% | ###ESSENCE showed 20% decrease in death, MI or urgent revasc w/ LMWH | ||
##Adjust for CrCl<30ml and extremes of weight | ##Adjust for CrCl<30ml and extremes of weight | ||
##No need to monitor labs | ##No need to monitor labs | ||
#Unfractionated Heparin | #Unfractionated Heparin | ||
##Consider if pt likely to undergo PCI/CABG within 24hr of admission | |||
##Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s | ##Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s | ||
#Hirudin | |||
##Approved only for pts w/ HIT | |||
===Thrombolytics=== | ===Thrombolytics=== | ||
| Line 82: | Line 88: | ||
==Source == | ==Source == | ||
Tintinalli | *Tintinalli | ||
*EM Practice Guidelines | |||
EM Practice | *UpToDate | ||
UpToDate | |||
[[Category:Cards]] | [[Category:Cards]] | ||
Revision as of 05:45, 17 April 2012
Background
- 33% w/ confirmed MI have no CP on presentation (esp older, female, DM, CHF)
- 5% of NSTEMI will develop Cardiogenic Shock (60% mortality)
- Age >65 w/ MI and anemia had 33% reduction in 30 day mort if transfused to keep HCT >30
- Association between quantity of troponin and risk of death
Diagnosis
Treatment
- Dual antiplatelet therapy is key
- ASA + other agent (other agent depends on conservative vs interventional strategy)
- Medical management vs cath determined by level of risk for future cardiovascular events
- ASA + other agent (other agent depends on conservative vs interventional strategy)
Anti-ischemia
- Oxygen
- ACC recs O2 for sats <90% (evidence indeterminant)
- Nitrates
- No mortality benefit
- Use cautiously in inferior MI
- Decreases preload
- B-block to avoid reflex tachycardia
- B-Blockers
- No IV BB in ED, PO w/in 24 H
- Goal HR is 50-60
- Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms
- Decreases progression from UA to MI by 13%
- Decr inotropic and chronotropic response to catechols
- Use diltif can't use beta-blocker (nifedipine clearly harmful)
- ACE Inhibitor
- start short-acting (captopril) w/in 24hr of admission
- Reduces RR of 30 day mort by 7%
- Those w/ recent MI (esp ant) and LV dysfunction benefit most
- Transfusion
- Transfuse to keep Hb>10
- Magnesium
- Reduces pain and theoretically can decr HR, SBP and O2 demand
- Correct hypomag
Antiplatelet
- ASA
- Recommended dose is 325mg chewed
- Reduces death from MI by 12.5-6.4%
- Should be used in all ACS unless contraindicated
- Clopidogrel
- Give in addition to ASA
- 300mg
- 600mg if going to PCI (superior in preventing post-proc MI)
- Mortality benefit with NSTEMI
- Main risk and contraindication is bleeding
- CURE trial: Decr in CV death, MI or stroke by 9.3-11.5%
- Give in addition to ASA
- GPIIb/IIIa Inhibitors
- Eptifibatide, abciximab, tirofiban
- Benefit only for pts undergoing PCI
- Administer at time of PCI, not in the ED
Antithombotics
- Give heparin or enoxaparin along w/ ASA (Class 1A evidence)
- Enoxaparin
- AHA recommends for moderate & high risk UA/NSTEMI unless CABG w/in 24hr
- 1mg/kg subq BID
- Safer than UFH
- ESSENCE showed 20% decrease in death, MI or urgent revasc w/ LMWH
- Adjust for CrCl<30ml and extremes of weight
- No need to monitor labs
- Unfractionated Heparin
- Consider if pt likely to undergo PCI/CABG within 24hr of admission
- Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s
- Hirudin
- Approved only for pts w/ HIT
Thrombolytics
- Only useful for STEMI
Angiography
- Indicated for:
- Recurrent angina/ischemia w/ or w/o sx of CHF
- Elevated troponins
- New or presumably new ST-segment depression
- High-risk findings on noninvasive stress testing
- Depressed LV function
- Hemodynamic instability
- Sustained V-tach
- PCI w/in previous 6 mo
- Prior CABG
See Also
Source
- Tintinalli
- EM Practice Guidelines
- UpToDate
